Daito Pharmaceutical Co.,Ltd.
4577.T · JPX
5/31/2025 | 5/31/2024 | 5/31/2023 | 5/31/2022 | |
|---|---|---|---|---|
| Market Cap | ¥29,965,401 | ¥17,464,083 | ¥16,555,142 | ¥18,211,617 |
| - Cash | ¥2,207,000 | ¥2,727,000 | ¥3,607,000 | ¥4,381,000 |
| + Debt | ¥11,885,000 | ¥8,719,000 | ¥4,958,000 | ¥3,447,000 |
| Enterprise Value | ¥39,643,401 | ¥23,456,083 | ¥17,906,142 | ¥17,277,617 |
| Revenue | ¥50,643,000 | ¥46,895,000 | ¥45,101,000 | ¥43,464,000 |
| % Growth | 8% | 4% | 3.8% | – |
| Gross Profit | ¥8,638,000 | ¥9,839,000 | ¥10,331,000 | ¥11,459,000 |
| % Margin | 17.1% | 21% | 22.9% | 26.4% |
| EBITDA | ¥7,413,000 | ¥7,920,000 | ¥8,958,000 | ¥9,881,000 |
| % Margin | 14.6% | 16.9% | 19.9% | 22.7% |
| Net Income | ¥1,908,000 | ¥3,295,000 | ¥3,600,000 | ¥4,668,000 |
| % Margin | 3.8% | 7% | 8% | 10.7% |
| EPS Diluted | 62.72 | 105 | 113.71 | 152.45 |
| % Growth | -40.3% | -7.7% | -25.4% | – |
| Operating Cash Flow | ¥5,897,000 | ¥5,182,000 | ¥4,155,000 | ¥4,370,000 |
| Capital Expenditures | -¥6,854,000 | -¥6,276,000 | -¥5,556,000 | -¥4,733,000 |
| Free Cash Flow | -¥957,000 | -¥1,094,000 | -¥1,401,000 | -¥363,000 |